Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

By /

Tenax Therapeutics, Inc. announced that the first patient has enrolled in the Company’s Phase 3 LEVEL Study.

Scroll to Top